"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
Kuric™ is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.
DOSAGE AND ADMINISTRATION
Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis and tinea (pityriasis) versicolor: It is recommended that Kuric™ be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment. Patients with tinea pedis require six weeks of treatment.
Seborrheic dermatitis: Kuric™ should be applied to the affected area twice daily for four weeks or until clinical clearing.
If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.
Kuric™ (ketoconazole) 2% cream is supplied as follows: 75 gram NDC 68712 006 03 Store below 77°F (25°C).
Manufactured for: JSJ Pharmaceuticals, 140 East Bay Street, Suite C, Charleston, SC 29401. www.jsjpharm.com, www.KuricCream.com. Manufactured by: Altana Inc. Melville, NY 11747. Revised: April 2007
Last reviewed on RxList: 8/23/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Kuric Information
Report Problems to the Food and Drug Administration
Find out what women really need.